Skip to content
STRATUM

DHTI

Dalrada Technology Group, Inc.
CIK 0000725394 · Services-Help Supply Services
Z″ LOWER ZONE
Z′ -11.61
Net margin
-121.4%
as of 2025-06-30
Operating margin
-100.8%
as of 2025-06-30
Revenue YoY growth
2.3%
as of 2025-06-30
Disclosure completeness
4 / 11

Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.

Provenance: DHTI’s most recent Revenue
$20,302,803
Filing
0001683168-25-007318 (10-K)
Period
2024-07-01 to 2025-06-30
XBRL tag
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Context
From2024-07-01to2025-06-30
Mapping
seed · confidence 1.00
View the filed document ↗
What the filing says drives results

Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

the Company continues to rely on equity and debt investors to finance its losses

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

The continuation of the Company as a going concern is dependent upon successful financing through equity and/or debt investors

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

Genefic Specialty Pharmacy’s debt service during fiscal year also affected revenue growth.

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

we funded our business operations, including capital expenditures and working capital requirements, principally from cash and cash equivalents and issuance of debt and common stock.

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

The increase in financing activities was primarily due to the draw down of various note payables to fund the company.

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

Our inability to raise additional capital on acceptable terms could have a material adverse effect on our business, prospects, results of operations, liquidity and financial condition.

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

any decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future

CAPITAL ACCESS LIQUIDITYItem 7 MD&A

There can be no assurance that we would be able to complete any proposed financing on terms acceptable to us, or at all